Orion and Shilpa Medicare Expand European Nivolumab Biosimilar Partnership
Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and long-term supply agreement with Orion Corporation for the development and commercialization of an intravenous (IV) biosimilar version of nivolumab, one of the world’s leading cancer immunotherapies. The collaboration is aimed at expanding patient access to high-quality biologic treatment options across Europe while supporting healthcare systems through the availability of more affordable biosimilar medicines.
The partnership combines Shilpa Biologicals’ expertise in biologics development and large-scale manufacturing with Orion Corporation’s established commercial presence throughout Europe. Under the agreement, Shilpa Biologicals will be responsible for developing the biosimilar product and serving as the exclusive long-term commercial manufacturer and supplier for the European market, while Orion will oversee regulatory approvals, commercialization, marketing, distribution, and sales across the region.
The agreement represents another important milestone in the growing collaboration between the two companies and reflects the increasing importance of biosimilars in improving access to advanced cancer therapies as several major biologic medicines approach the end of their market exclusivity.
Expanding Access to Immuno-Oncology Therapies
Nivolumab is among the most widely used immune checkpoint inhibitors in oncology and has played a transformative role in the treatment of multiple cancers since its introduction.
As a programmed death-1 (PD-1) immune checkpoint inhibitor, nivolumab helps restore the immune system’s ability to recognize and attack cancer cells. By blocking the interaction between PD-1 receptors on T cells and their corresponding ligands on tumor cells, the therapy enhances antitumor immune responses and enables the body’s immune defenses to more effectively target malignant cells.
The introduction of nivolumab helped establish the field of immuno-oncology as one of the most significant advances in modern cancer treatment.
Today, the medicine is used across numerous tumor types, including melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, bladder cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, and several other malignancies, either as monotherapy or in combination with additional anticancer treatments.
Its broad clinical utility has made nivolumab one of the highest-selling oncology biologics globally.
Opportunity Created by Loss of Exclusivity
As the originator product approaches the expiration of key intellectual property protections across Europe, opportunities are emerging for biosimilar developers to introduce lower-cost alternatives.
The availability of biosimilars following loss of exclusivity has consistently contributed to increased patient access while helping healthcare systems manage the rising costs associated with biologic therapies.
According to market data cited by the companies, nivolumab generated approximately USD 4.1 billion in European sales during 2025, highlighting both its widespread clinical use and the substantial commercial opportunity associated with introducing a biosimilar version.
The large patient population receiving nivolumab also underscores the potential healthcare impact that affordable biosimilars could have by expanding access to treatment while reducing financial pressure on national healthcare budgets.
Complementary Strengths Drive Collaboration
The newly announced agreement leverages the complementary capabilities of both organizations.
Shilpa Biologicals has established expertise in the research, development, process optimization, manufacturing, and supply of complex biologic medicines.
The company has invested significantly in biologics infrastructure, including manufacturing facilities designed to comply with stringent international quality standards.
Orion Corporation, meanwhile, possesses an extensive commercial infrastructure across Europe and longstanding experience in bringing pharmaceutical products to hospital and specialty care markets.
By combining Shilpa’s manufacturing capabilities with Orion’s commercial reach, the companies aim to efficiently develop and launch the biosimilar across multiple European countries once regulatory approvals have been obtained.
The collaboration is expected to streamline product development while accelerating market availability following patent expiry.
Clearly Defined Responsibilities
The agreement establishes distinct responsibilities for each partner throughout the product lifecycle.
Shilpa Biologicals will lead the scientific development of the intravenous nivolumab biosimilar, including analytical characterization, process development, manufacturing scale-up, and regulatory support.
Following successful approval, the company will also serve as the exclusive long-term commercial manufacturer and supplier for European markets.
This arrangement positions Shilpa Biologicals as the primary production partner responsible for ensuring continuous product availability and maintaining compliance with European manufacturing requirements.
Orion Corporation will hold exclusive rights for regulatory registration, commercialization, marketing, distribution, and sales of the biosimilar throughout Europe.
Its responsibilities include obtaining marketing authorizations from European regulatory authorities, launching the product across eligible markets, engaging healthcare providers, and supporting commercial adoption.
Long-Term Commercial Framework
Beyond product development, the collaboration establishes a long-term commercial relationship between the companies.
Under the financial terms of the agreement, Shilpa Biologicals will receive milestone payments tied to development progress and regulatory achievements.
These payments recognize successful advancement through key stages of clinical development and regulatory review.
Once commercial sales begin, Shilpa will also generate ongoing revenue through long-term manufacturing and product supply for Orion.
This combination of milestone income and sustained manufacturing revenue provides the company with both near-term and long-term financial opportunities while reinforcing its role as a global contract development and manufacturing partner for complex biologics.
Supporting High-Quality European Manufacturing Standards
An important component of the partnership is the commitment to manufacturing the biosimilar according to European Union Good Manufacturing Practice (EU-GMP) standards.
EU-GMP certification represents one of the highest international benchmarks for pharmaceutical manufacturing quality, ensuring rigorous controls over production processes, quality management systems, product consistency, and patient safety.
Compliance with these standards is essential for obtaining regulatory approval within Europe and maintaining confidence among physicians, healthcare institutions, and patients.
The companies emphasized that the biosimilar will be manufactured according to these stringent quality requirements, supporting reliable long-term supply across European healthcare systems.
Leadership Highlights Strategic Importance
Commenting on the agreement, Vishnukant Bhutada, Managing Director of Shilpa Medicare, described the collaboration as an important milestone in the continued growth of Shilpa Biologicals.
He noted that extending the existing partnership with Orion into the rapidly expanding field of immuno-oncology demonstrates the confidence international partners place in the company’s scientific capabilities, manufacturing expertise, and ability to produce complex biologic medicines at commercial scale.
According to Bhutada, the agreement reflects years of investment in advanced biologics research and manufacturing infrastructure and reinforces Shilpa’s commitment to expanding access to innovative therapies through high-quality biosimilar development.
The partnership also strengthens the company’s strategic position within the global biologics market, which continues to experience robust growth as more originator biologic medicines approach patent expiry.
Orion Expands Its Hospital Portfolio
From Orion’s perspective, the collaboration aligns closely with its strategy of expanding access to affordable, high-quality medicines throughout Europe.
Satu Ahomäki, Executive Vice President of Generics and Consumer Health at Orion Pharma, stated that the addition of another product to the strategic collaboration with Shilpa further strengthens the relationship between the two companies.
She explained that the agreement supports Orion’s efforts to reinforce its presence within the hospital segment across continental Europe while advancing the broader objectives of its generics business.
According to Ahomäki, increasing access to affordable quality medicines remains a central element of Orion’s long-term strategy, and the nivolumab biosimilar partnership represents another step toward achieving that objective.
Growing Importance of Biosimilars in Oncology
The agreement reflects broader trends occurring across the global pharmaceutical industry.
As numerous blockbuster biologic therapies lose patent protection, biosimilars have become increasingly important in expanding patient access to advanced treatments while helping healthcare systems manage escalating oncology costs.
Unlike generic versions of conventional small-molecule drugs, biosimilars require sophisticated manufacturing technologies and extensive analytical comparisons to demonstrate high similarity to the reference biologic.
Successful development therefore requires substantial scientific expertise, advanced manufacturing capabilities, and rigorous quality control systems.
Companies capable of meeting these requirements are increasingly forming strategic collaborations that combine development expertise with established commercial networks.
The Shilpa-Orion partnership represents this evolving model, allowing each organization to contribute its core strengths while accelerating patient access to high-quality biosimilar medicines.
The co-development and supply agreement between Shilpa Biologicals and Orion Corporation marks an important advancement in the expanding European biosimilars market. By combining Shilpa’s expertise in biologics development and EU-GMP manufacturing with Orion’s established commercial presence across Europe, the partnership aims to bring a high-quality intravenous nivolumab biosimilar to patients following the reference product’s loss of exclusivity.
With nivolumab representing one of the most widely prescribed immuno-oncology therapies and generating approximately USD 4.1 billion in European sales during 2025, the collaboration has the potential to significantly expand patient access while supporting healthcare sustainability through more affordable treatment options. As development progresses toward future regulatory submissions, the partnership also reinforces both companies’ long-term commitment to delivering innovative, high-quality biologic medicines that improve cancer care across Europe.
About Shilpa Medicare Limited
Shilpa Medicare, headquartered in India, is a diversified pharmaceutical and biotechnology company developing complex generics, biologics and APIs. Through Shilpa Biologicals, it operates an integrated biologics platform spanning development, scale-up and commercial manufacturing at its EU-GMP facility in Dharwad.
About Orion Corporation
Orion Pharma is a globally operating Nordic pharmaceutical company and a builder of well-being for over a hundred years. It develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with an extensive portfolio of proprietary and generic medicines and consumer health products. Its core R&D areas are oncology and pain, with proprietary products treating cancer, respiratory and neurological diseases, among others. In 2025, net sales amounted to EUR 1,890 million, with about 4,000 employees worldwide.